Acceleration of RAD204 Phase 1 dose escalation trial
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
12 May 2025
Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose
Escalation Clinical Trial Based on Positive Recommendation from
Data Safety and Monitoring Committee (DSMC)
DSMC concluded that Phase 1 study may continue as planned without any modifications
On track to complete the enrollment of the first two cohorts by mid-2025
Sydney, Australia – 12 May 2025 – Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX,
“Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on
developing innovative oncology radiopharmaceuticals for areas of high unmet medical need,
announced today that it has achieved a key milestone in its ongoing clinical development program
for its clinical-stage radiotherapeutic asset, 177Lu-RAD204, as the Data and Safety Monitoring
Committee (DSMC) has approved to proceed to the next dose in its Phase 1 clinical trial in patients
with PD-L1 positive advanced cancers1. The DSMC is an independent multidisciplinary group that
conducts detailed reviews of unblinded study data, discusses potential safety concerns and provides
recommendations regarding trial continuation.
“We greatly appreciate the DSMC’s judicious review of our first cohort of patients in the Phase 1
study of Lu177-RAD204, which allows us to advance to the higher dose cohort in a variety of PD-L1driven cancers,” said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics.
“With this clearance from the DSMC, the increased number of active centers and expansion to
multiple tumor types beyond Non-Small Cell Lung Cancer (NSCLC), we expect to accelerate our
timelines for complete enrolment of the next cohort by mid-2025. We believe that RAD204 has the
potential to strongly improve clinical outcomes for patients with PD-L1 positive advanced cancers
and we look forward to seeing data from the first two cohorts of patients later this year.”
The DSMC reviewed the first cohort of four patients treated with 30mCi of Lu177-RAD204 and
confirmed that there was positive safety, pharmacokinetic and biodistribution data and agreed that
the study may continue without modifications. The second cohort of patients will start at 60mCi of
Lu177 rather than 40mCi previously assumed in the protocol. The second cohort of patients is
expected to be enrolled by mid-year 2025 and will include expansion to multiple tumor types
including NSCLC, Small-Cell Lung Cancer (SCLC), Triple-negative Breast Cancer (TNBC), Cutaneous
Melanoma, head and neck squamous cell carcinoma (HNSCC) and Endometrial Cancer.
There are currently four clinical trial sites actively screening and recruiting patients in Australia.
About 177Lu-RAD204:
RAD204 is a single-domain monoclonal antibody (sdAb) that targets PD-L1, a protein that helps
control the immune system and is overexpressed in many solid cancers, making it an attractive
therapeutic target in multiple tumor types, including NSCLC, SCLC, TNBC, Cutaneous Melanoma,
HNSCC, and Endometrial Cancer. Previously published Phase I imaging data of 16 NSCLC patients
1
ClinicalTrials.gov ID: NCT06305962
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
ASX ANNOUNCEMENT
12 May 2025
with 99Tc-RAD204 demonstrated that the diagnostic compound is safe and is associated with
acceptable dosimetry2.
Tumor targeting with radioimmunotherapies such as 177Lu-RAD204 has the potential to address
resistance mechanisms to current standard-of-care treatment options.
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class
platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in
areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The
company has a pipeline of distinct and highly differentiated platform technologies spanning
peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes
one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and
brain. Learn more at radiopharmtheranostics.com.
Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman
Paul Hopper.
For more information:
Investors:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com
Anne Marie Fields
Precision AQ (formerly Stern IR)
E: annemarie.fields@precisionaq.com
Media:
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au
Follow Radiopharm Theranostics:
Website – https://radiopharmtheranostics.com/
X – https://x.com/TeamRadiopharm
LinkedIn – https://www.linkedin.com/company/radiopharm-theranostics/
InvestorHub – https://investorhub.radiopharmtheranostics.com/
2
Xing Y, et al. J Nucl Med. 2019 Sep;60(9):1213-1220.
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
Share your feedback
Discover